HPV関連がん治療モニタリングにおけるリキッドバイオプシーの役割
リキッドバイオプシー - HPV 関連疾患の治療モニタリングと早期再発検出のための可能なツール
This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.
調査の概要
状態
詳細な説明
Although the cancers associated with human papillomavirus (HPV) infection are currently almost entirely preventable, a significant part of the Czech population suffers from these diseases. The most common HPV-associated cancers are cervical cancer (CC) and oropharyngeal cancer (OPC). In these, the severe problem is successful monitoring of the treatment effectiveness and early disease recurrence detection. It is, therefore, necessary to find a non-invasive method that could specifically and timely identify patients at risk of recurrence and thus enable patients with quality and less burdensome medical care. The use of liquid biopsies (LB), which the study focuses on, looks most promising.
This study is divided into two arms, with each arm including both prospective and retrospective parts. Into prospective parts will be enrolled only newly diagnosed CC/HSIL (high-grade cervical intraepithelial lesions) or OPC patients. In contrast, the retrospective part will enroll patients in post-treatment follow-up. In both study arms, fresh tumor tissues will be sampled from patients in prospective parts before treatment, and archived Formalin Fixed Paraffin Embedded (FFPE) tissue samples will be obtained from patients of retrospective parts.
Regarding the liquid biopsies, pre & post-treatment sampling of LB will be performed. Subsequently, regular sample acquisition will be performed during follow-up according to the standard medical practice in both prospective and retrospective parts. Oropharyngeal swabs, gargle lavage,exhaled breath condensate (EBC), and blood samples will be collected from OPC patients. Blood collection and self-sampling of cervicovaginal swabs will be performed in patients with CC/HSIL. All samples, excluding blood samples, will be tested for the presence of the most prevalent high-risk and low-risk HPV genotypes. The circulating tumor (ct) HPV DNA will be monitored in blood samples. Additionally, the mutation profile of the primary tumors will be examined in fresh and FFPE samples.
The dynamics of HPV DNA will be monitored throughout all follow-up samples and correlated with the obtained clinical data. A created panel of frequently altered genes will be used for alterations monitoring in liquid biopsies. In the final analysis of laboratory and clinical results, we assume a finding of a clinically usable algorithm that could predict the risk of disease recurrence for a particular patient.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Vladimira Koudelakova, MSc, Ph.D.
- 電話番号:+420 585 632 089
- メール:vladimira.koudelakova@upol.cz
研究連絡先のバックアップ
- 名前:Marian Hajduch, MD., PhD.
- 電話番号:+420 585 632 083
- メール:marian.hajduch@upol.cz
研究場所
-
-
-
Olomouc、チェコ、77900
- 募集
- University Hospital Olomouc
-
コンタクト:
- Marian Hajduch, MD, PhD.
- 電話番号:+420 585 632 083
- メール:marian.hajduch@upol.cz
-
コンタクト:
- Vladimira Koudelakova, MSc., PhD.
- 電話番号:+420 585 632 089
- メール:vladimira.koudelakova@upol.cz
-
主任研究者:
- Radovan Pilka, prof. MD,PhD
-
主任研究者:
- Richard Salzman, MD, PhD.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Oropharyngeal cancer patients, Cervical cancer patients
説明
Inclusion Criteria:
Women diagnosed with CC/HSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent.
Exclusion Criteria:
No exclusion criteria are set.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:OTHER
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Arm A - Oropharyngeal cancer patients
In total, approx. 200 OPC cancer patients will be enrolled in the study Arm A, with both prospective and retrospective parts enrolling 100 OPC patients. The Arm A will enroll patients from the Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (gargle lavage, oropharyngeal smear, breath condensate, and blood sample) will be collected. Obtained samples will be tested by CE-IVD (device complies with European in vitro diagnostic Directive) marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 3 years and every 6 months for 2 years. |
Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians. |
|
Arm B - Cervical cancer patients
Into the study Arm B will be enrolled 80 patients with CC and 120 patients with HSIL, and 80 patients will be enrolled into the retrospective part. The Arm B will enroll patients from the Department of Gynecology and Obstetrics, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (cervicovaginal swab and blood sample) will be collected. Obtained samples will be tested by CE-IVD marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 2 years and every 6 months for 3 years. |
Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dynamics of HPV infection in cervical cancer patients during 4-year follow-up.
時間枠:4 years
|
HPV-status in liquid biopsies collected during pre-treatment, post-treatment and follow-up check-ups. |
4 years
|
|
Dynamics of HPV infection in oropharyngeal cancer patients during 4-year follow-up.
時間枠:4 years
|
HPV-status in liquid biopsies collected during pre-treatment, post-treatment and follow-up check-ups. |
4 years
|
|
Dynamics of circulating tumor (ct) HPV DNA in oropharyngeal cancer patients.
時間枠:4 years
|
Correlation of plasmatic ct HPV DNA level with cancer patient´s prognosis. |
4 years
|
|
Dynamics of circulating tumor (ct) HPV DNA in cervical cancer patients
時間枠:4 years
|
Correlation of plasmatic ct HPV DNA level with patient´s prognosis |
4 years
|
|
Analysis of the mutational landscape of oropharyngeal cancer cases.
時間枠:4 years
|
Correlation of tumor mutational burden (TMB) with cancer patient´s prognosis. |
4 years
|
|
Analysis of the mutational landscape of cervical cancer cases.
時間枠:4 years
|
Correlation of tumor mutational burden (TMB) with cancer patient´s prognosis. |
4 years
|
協力者と研究者
捜査官
- スタディディレクター:Marian Hajduch, MD., PhD.、IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 顎口腔疾患
- 病理学的プロセス
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 疾患の属性
- 感染症
- ウイルス病
- 子宮の病気
- 生殖器疾患、女性
- 頭頸部腫瘍
- 伝染病
- 性感染症、ウイルス
- 性感染症
- DNAウイルス感染症
- 性器腫瘍、女性
- 前がん状態
- 子宮頸部疾患
- 耳鼻咽喉科疾患
- 子宮腫瘍
- 咽頭腫瘍
- 耳鼻咽喉科の新生物
- 咽頭疾患
- 腫瘍ウイルス感染症
- 病理学的状態、徴候および症状
- 子宮頸部腫瘍
- パピローマウイルス感染症
- 子宮頸部異形成
- 中咽頭腫瘍
- 調査手法
- 標本処理
- 臨床検査技術
- 診断技術と手順
- 診断
- 細胞学的技術
- 生検
- 細胞診断
- 液体生検
その他の研究ID番号
- NU-23-03-00255
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。